| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations (NCT06892522) | AbbVie | 2025-06-30 |
| A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants (NCT07015398) | Trevi Therapeutics | 2025-06-30 |
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects (NCT07035665) | Chengdu Suncadia Medicine Co., Ltd. | 2025-06-30 |
| A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors (NCT06873789) | Incyte Corporation | 2025-06-30 |
| A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (NCT06009107) | Juventas Cell Therapy Ltd. | 2025-06-30 |
| A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors (NCT07003139) | China Medical University Hospital | 2025-06-30 |
| A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury (NCT06841770) | Lineage Cell Therapeutics, Inc. | 2025-06-30 |
| A Study on Bioequivalence of Cabergoline Tablets in Human Body (NCT07008417) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-06-30 |
| A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors (NCT07071090) | Heronova Pharmaceuticals | 2025-06-30 |
| A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) (NCT07043946) | Climb Bio, Inc. | 2025-06-30 |
| An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer (NCT07053735) | Peking University First Hospital | 2025-06-30 |
| PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer (NCT07031011) | jiuwei cui | 2025-06-30 |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer (NCT06966453) | Pfizer | 2025-06-30 |
| Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy (NCT07012304) | Yujun DONG | 2025-06-30 |
| Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants (NCT07011511) | Medicines for Malaria Venture | 2025-06-30 |
| Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects (NCT06920719) | Yuhan Corporation | 2025-06-29 |
| Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors. (NCT07040943) | West China Hospital | 2025-06-29 |
| Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation (NCT07034950) | The First Affiliated Hospital of Xiamen University | 2025-06-29 |
| Regenerative Endodontic Treatment Using Sodium Hexametaphosphate (SHMP) For Necrotic Immature Permanent Anterior Teeth (NCT07097688) | Ahmad Elheeny | 2025-06-29 |
| Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells (NCT07041801) | Shenzhen Beike Bio-Technology Co., Ltd. | 2025-06-28 |
| Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study (NCT07169487) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (NCT07153068) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (NCT07109518) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies (NCT07106749) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-28 |
| Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma (NCT06169280) | Northwestern University | 2025-06-27 |
| Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG) (NCT06600178) | University of Virginia | 2025-06-27 |
| Study of CM518D1 in Patients With Advanced Solid Tumors (NCT07019779) | Keymed Biosciences Co.Ltd | 2025-06-27 |
| A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease (NCT07170475) | Fujita Health University | 2025-06-27 |
| A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants (NCT07051993) | Genentech, Inc. | 2025-06-27 |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) (NCT05733689) | University of California, Irvine | 2025-06-27 |
| Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage (NCT07053852) | Sherrif Ibrahim | 2025-06-27 |
| A Phase I Study of SNH-119014 in Healthy Volunteers (NCT07087262) | ScinnoHub Pharmaceutical Co., Ltd. | 2025-06-27 |
| A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP (NCT07119125) | Monte Rosa Therapeutics, Inc | 2025-06-27 |
| A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 (NCT06965751) | University of Melbourne | 2025-06-27 |
| Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma (NCT07027748) | Steven DuBois, MD | 2025-06-27 |
| A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses (NCT07063342) | Bristol-Myers Squibb | 2025-06-27 |
| A Phase I Study of HW201877 in Healthy Subjects (NCT07373457) | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | 2025-06-26 |
| Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients (NCT07096869) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2025-06-26 |
| Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH) (NCT06826859) | Thomas Jefferson University | 2025-06-26 |
| Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care (NCT07034963) | The First Affiliated Hospital of Xiamen University | 2025-06-26 |
| An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults (NCT07016152) | Cho Pharma Inc. | 2025-06-26 |
| A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy (NCT07483827) | eleva GmbH | 2025-06-26 |
| A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) (NCT07035626) | West China Hospital | 2025-06-25 |
| Clenbuterol to Target DUX4 in FSHD (NCT06721299) | Jeffrey Statland | 2025-06-25 |
| Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma (NCT06861452) | EIR Biotherapies s.r.l. | 2025-06-25 |
| Phase I Study of MT1011 Injection in Healthy Subjects (NCT07024160) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2025-06-25 |
| Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 (NCT07264569) | Henan Cancer Hospital | 2025-06-25 |
| Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (NCT06819735) | Domain Therapeutics Australia Pty Ltd | 2025-06-25 |
| TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (NCT06961786) | TILT Biotherapeutics Ltd. | 2025-06-25 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD (NCT06843408) | Incyte Corporation | 2025-06-25 |
| Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents (NCT06963346) | H. Lee Moffitt Cancer Center and Research Institute | 2025-06-24 |
| The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects. (NCT06994286) | Tanabe Pharma Corporation | 2025-06-24 |
| A Study of Remternetug (LY3372993) in Healthy Participants (NCT07056309) | Eli Lilly and Company | 2025-06-24 |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies (NCT06994806) | Kumquat Biosciences Inc. | 2025-06-24 |
| A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors (NCT07036185) | Shanghai Bao Pharmaceuticals Co., Ltd. | 2025-06-24 |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors (NCT07020221) | Verastem, Inc. | 2025-06-24 |
| A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis (NCT07029971) | Vial Australia Pty Ltd | 2025-06-23 |
| Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause (NCT07118891) | AbCellera Biologics Inc. | 2025-06-23 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure (NCT07708194) | Tianjin Medical University Cancer Institute and Hospital | 2025-06-23 |
| An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis (NCT06946199) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-06-23 |
| A Phase I Dose Finding Study of MB-CART2219.1 (NCT07108868) | University Hospital Tuebingen | 2025-06-23 |
| Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study (NCT07028047) | Sun Yat-sen University | 2025-06-23 |
| Phase I/II Study of SCTB39-1 in Advanced Solid Tumours (NCT07050641) | Sinocelltech Ltd. | 2025-06-23 |
| A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration (NCT07024732) | Eyevensys | 2025-06-23 |
| TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas (NCT07082803) | Treeline Biosciences, Inc. | 2025-06-23 |
| Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects (NCT07049107) | Jiangsu HengRui Medicine Co., Ltd. | 2025-06-23 |
| A Study of [14C]-LY4065967 in Healthy Participants (NCT07039045) | Eli Lilly and Company | 2025-06-23 |
| Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (NCT06696768) | National Cancer Institute (NCI) | 2025-06-23 |
| Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole) (NCT07266792) | Humanis Saglık Anonim Sirketi | 2025-06-22 |
| A Phase 1 Study of KHN702 Tablets in Healthy Subjects (NCT07044960) | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 2025-06-21 |
| BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma (NCT07009002) | Chinese PLA General Hospital | 2025-06-20 |
| Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture (NCT06949137) | HELP Therapeutics Co., Ltd. | 2025-06-20 |
| Clinical Trial of Intranasal Delivery of NT-301 (NCT06954428) | Nano PharmaSolutions Australia | 2025-06-20 |
| Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) (NCT06977711) | The University of Texas Health Science Center at San Antonio | 2025-06-20 |
| A Study to Learn How the Study Medicine Called [14C]PF-07054894 is Processed by the Body (NCT07009353) | Pfizer | 2025-06-20 |
| BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL (NCT07008885) | Chinese PLA General Hospital | 2025-06-20 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults (NCT06965465) | Pfizer | 2025-06-20 |
| A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease (NCT07048197) | Novartis Pharmaceuticals | 2025-06-20 |
| Oral Steroid Taper After Total Knee Arthroplasty (NCT07070882) | Columbia University | 2025-06-20 |
| PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma (NCT07007117) | Stephan Grupp MD PhD | 2025-06-20 |
| MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease. (NCT07000292) | Shanghai Changzheng Hospital | 2025-06-20 |
| A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects (NCT07014488) | Jiangsu HengRui Medicine Co., Ltd. | 2025-06-20 |
| A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma (NCT07015749) | The First Affiliated Hospital of Soochow University | 2025-06-20 |
| PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma (NCT07018518) | Chinese PLA General Hospital | 2025-06-20 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants (NCT06868082) | Uniquity One (UNI) | 2025-06-20 |
| A First-in-Human Study of PRD001 (NCT07034183) | PRD Therapeutics, Inc. | 2025-06-19 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age (NCT05956821) | University of Miami | 2025-06-19 |
| CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia (NCT06622694) | Institute of Hematology & Blood Diseases Hospital, China | 2025-06-19 |
| REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study (NCT06998706) | Ruijin Hospital | 2025-06-19 |
| Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (NCT06984094) | Clover Biopharmaceuticals AUS Pty | 2025-06-18 |
| PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) (NCT06920628) | National Institute of Mental Health (NIMH) | 2025-06-18 |
| A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors (NCT06992713) | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | 2025-06-18 |
| REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study (NCT06987214) | Ruijin Hospital | 2025-06-18 |
| A Study to Evaluate MWN109 Tablets in Healthy Adult Participants (NCT06938269) | Shanghai Minwei Biotechnology Co., Ltd | 2025-06-18 |
| Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers (NCT07113106) | ANRS, Emerging Infectious Diseases | 2025-06-18 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years (NCT07543198) | Sinovac Life Sciences Co., Ltd. | 2025-06-18 |
| Opioid Antagonism in Hypogonadotropic Hypogonadism (NCT04975334) | Stephanie B. Seminara, MD | 2025-06-18 |
| A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults (NCT07035769) | Debiopharm International SA | 2025-06-18 |
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma (NCT06894979) | Children's Oncology Group | 2025-06-18 |
| A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus (NCT06988553) | Eccogene | 2025-06-17 |